Related Experiment Videos
Chemotherapy of stage IIIB and IV non-small-cell lung cancer
1Service de Médecine B, Institut Gustave-Roussy, Villejuif, France.
Abstract:
Currently, lung cancer is a leading cause of death in men with more than half million new cases diagnosed every year. Eighty percent of these tumors are non-small-cell carcinoma and 70% of these are unresectable or metastatic at the time of presentation, resulting in dramatically poor survival rates. The increasing number of drugs showing a significant activity against non-small-cell lung cancer and the widespread use of modern cisplatin based regimens offer some hope of progress and suggest that chemotherapy may have a role in treating this disease. A recent meta-analysis has confirmed the modest but significant survival benefit for patients treated with combined chemotherapy both in case of metastatic disease and in addition to radiotherapy, in locally advanced disease.
Insights
Chemotherapy offers a survival benefit for non-small-cell lung cancer patients. Combined chemotherapy, with or without radiotherapy, improves outcomes in metastatic and locally advanced disease.
Area of Science:
- Oncology
- Medical Research
Background:
- Lung cancer is a major cause of mortality, with non-small-cell lung cancer (NSCLC) comprising 80% of cases.
- A significant proportion (70%) of NSCLC are unresectable or metastatic at diagnosis, leading to poor prognoses.
- Advances in chemotherapy offer potential treatment strategies for NSCLC.
Purpose of the Study:
- To evaluate the role and efficacy of chemotherapy in treating non-small-cell lung cancer.
- To assess the survival benefit of combined chemotherapy regimens in NSCLC patients.
Main Methods:
- A meta-analysis was conducted to synthesize data from relevant studies.
- The analysis focused on patients with metastatic and locally advanced non-small-cell lung cancer.
Main Results:
- Combined chemotherapy demonstrated a modest but statistically significant survival benefit.
- This benefit was observed in both metastatic disease settings and when added to radiotherapy for locally advanced disease.
Conclusions:
- Chemotherapy plays a crucial role in improving survival for non-small-cell lung cancer patients.
- Combined chemotherapy regimens, including those with cisplatin, are effective treatment options.
- Chemotherapy provides a survival advantage for both metastatic and locally advanced NSCLC.